Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2023-12-15
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Hepatitis C and setting up and testing new methods and implementation into the system of social health care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation Study of HCV RDTs in Fresh Samples
NCT04139941
Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population
NCT05146609
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
NCT01195181
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
NCT01329913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main goal of the project is the elimination of further transmission of hepatitis C virus and to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Hepatitis C and setting up and testing new methods and implementation into the system of social health care.
The project will include testing the procedure on a sample of approx. 3,000 PWID which can help to identify weak points in the continuum of care. A methodology for the continuous care of the target group in the early diagnostic and therapeutic stages will be created. Proposal for a system change towards streamlining the screening process.
The project is supported by the European Social Fund (Operational Program Employment plus) and the state budget of the Czech Republic and is registered by the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22\_005/0000281.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People who inject drugs
Hepatitis C antibody (anti-HCV) test
Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
Hepatitis C RNA test and genotype test
RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hepatitis C antibody (anti-HCV) test
Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
Hepatitis C RNA test and genotype test
RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* an active injecting drug user or have used injecting drugs at any time in the past
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute for Clinical and Experimental Medicine
OTHER_GOV
Brno University Hospital
OTHER
České Budějovice Hospital
OTHER
University Hospital Hradec Kralove
OTHER
University Hospital Olomouc
OTHER
Hepatogastroenterology Hradec Kralove
UNKNOWN
Regional Hospital Karlovy Vary
UNKNOWN
Clinic Podane ruce
UNKNOWN
Tomáš Baťa Regional Hospital in Zlín
UNKNOWN
Hospital Agel Prostějov
UNKNOWN
Hospital Jihlava
UNKNOWN
Hospital Havířov
UNKNOWN
Hospital Tábor
UNKNOWN
Remedis Prague
UNKNOWN
Hospital Opava
UNKNOWN
Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.
OTHER
Military University Hospital, Prague
OTHER
Hospital Pardubice
UNKNOWN
Institute of Health Information and Statistics of the Czech Republic
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Viktor Mravcik, assoc. prof.
Role: STUDY_DIRECTOR
Charles University First Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brno University Hospital
Brno, , Czechia
Clinic Podane ruce
Brno, , Czechia
České Budějovice Hospital
České Budějovice, , Czechia
Hospital Havířov
Havířov, , Czechia
Hepatogastroenterology Hradec Kralove
Hradec Králové, , Czechia
University Hospital Hradec Kralove
Hradec Králové, , Czechia
Hospital Jihlava
Jihlava, , Czechia
Regional Hospital Karlovy Vary
Karlovy Vary, , Czechia
University Hospital Olomouc
Olomouc, , Czechia
Hospital Opava
Opava, , Czechia
Hospital Pardubice
Pardubice, , Czechia
Institute for Clinical and Experimental Medicine
Prague, , Czechia
Military University Hospital, Prague
Prague, , Czechia
Remedis Prague
Prague, , Czechia
Hospital Agel Prostějov
Prostějov, , Czechia
Hospital Tábor
Tábor, , Czechia
Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.
Ústí nad Labem, , Czechia
Tomáš Baťa Regional Hospital in Zlín
Zlín, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UZIS 2023/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.